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Abstract
Background: Despite the known positive effects of cardiac rehabilitation and an active lifestyle, evidence is
emerging that it is difficult to attain and sustain the minimum recommendations of leisure time physical activity.
The long-term benefits are often disappointing due to lack of adherence to the changes in life style. Qualitative
research on patients’ perspectives suggests that motivation for lifestyle change tends to diminish around 3 months
after the index-event. The time most cardiac rehabilitation programmes end. The aim of the present study is to
determine if prolongation of a traditional cardiac rehabilitation programme with additional heart rate based
telemonitoring guidance for a period of 6 months results in better long term effects on physical and mental
outcomes, care consumption and quality of life than traditional follow-up.
Methods: In this single centre randomised controlled trial 120 patients with an absolute indication for cardiac
rehabilitation will be randomised in a 1:1 ratio to an intervention group with 6 months of heart rate based
telemonitoring guidance or a control group with traditional follow-up after cardiac rehabilitation. The primary
endpoint will be VO2peak after 12 months. Secondary endpoints are VO2peak after 6 months, quality of life, physical-,
emotional- and social functioning, cardiac structure, traditional risk profile, compliance to the use of the heart rate
belt and smartphone, MACE and care-consumption.
Discussion: The TeleCaRe study will provide insight into the added value of the prolongation of traditional cardiac
rehabilitation with 6 months of heart rate based telemonitoring guidance.
Trial registration: Dutch Trial Register: NTR4644 (registered 06/12/14).
Keywords: Cardiac rehabilitation, Telemonitoring and telecoaching, VO2, Cardio respiratory fitness, Leisure time
physical activity, Randomised controlled trial
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Background
Despite the known positive effects of Cardiac Rehabilitation
(CR) and an active lifestyle, evidence is emerging that it is
difficult to attain and sustain the minimum recommenda-
tions of Leisure Time Physical Activity (LTPA) [1, 2]. The
long-term benefits of CR are often disappointing due to
lack of adherence to the changes in life style [3, 4].
Cardiovascular diseases (CVD) are the leading cause of
death and a major cause of disability and lost productivity
in adults worldwide [5]. The aging and growth of the
population have offset reduction in cardiovascular mor-
tality in the past decade [6].
Both LTPA and Cardio Respiratory Fitness (CRF) are in-
versely correlated with mortality [7]. Lee et al. evaluated
the long-term effects of changes in CRF on cardiovascular
mortality. They observed a significant reduction in car-
diovascular mortality of 27 % and 42 %, respectively
(compared to those with a loss of CRF) in individuals who
had either no change or improvements in CRF. The mean
interval between the baseline and last examination being
6.3 years. For every 1-MET (Metabolic Equivalent of Task)
increase in CRF over time, all-cause and cardiovascular
mortality were reduced by 15 % and 19 %, respectively,
showing that even small improvements in CRF can have a
substantial effect [8].
Qualitative research on patients’ perspectives suggests
that motivation for lifestyle change tends to wane
around 3 months after the event, when the initial shock
has worn off, and most patients start feeling better [9].
In addition to the already low uptake of CR in the
Netherlands median total training duration seems to be
less than 3 months [10, 11]. Consolidating lifestyle habits
require continued attention and appropriate guidance
[3]. The transition of a supervised and structured train-
ing programme to a continuation without this guidance
could be a possible explanation for the low compliance
[12]. A better self-efficacy by telemonitoring could help
them to be engaged in and actually perform healthy be-
haviour (e.g. exercise adherence).
The main aim of the present study is to determine
whether prolongation of a traditional CR programme
with heart rate based telemonitoring guidance for a
period of 6 months results in better long-term effects on
physical and mental outcomes, care consumption and
quality of life (QOL). In order to see whether patients
are able to sustain their CRF and LTPA levels after the
telemonitoring intervention of 6 months, this will be
followed by a 6-month period without telemonitoring
guidance.
The primary objective of the study is to assess whether
the addition of 6 months of heart rate based telemoni-
toring guidance to the traditional CR programme results
in a higher peak oxygen uptake (VO2peak) than a regular
follow-up 12 months after CR. Secondary outcome pa-
rameters are: VO2peak at 6 months, cardiac structure and
function, QOL, physical (LTPA level), emotional and so-
cial functioning, traditional risk profile, compliance to
the use of the smartphone, adherence to the minimum
recommendations of LTPA, care consumption (hospital
admissions, outpatient clinic visits, general practitioner
(GP) visits, cardiovascular interventions and lab testing)
and Major Adverse Cardiac Events (MACE).
Methods
Design
This study is designed as a prospective single centre ran-
domised controlled trial. Patients will be evaluated at
baseline (T0), after 26 weeks (T1) and 12 months (T2)
after randomisation. Figure 1 provides a flowchart of the
study protocol. The study complies with the World
Medical Association Declaration of Helsinki on ethics in
medical research and is approved by the medical ethics
committee of Isala (NL48475.075.14; 14.0334). Clinical
Trial Registration: NTR4644.
Patients
The study will enrol in total 120 patients referred to the
CR centre of Isala Zwolle. Patients with a minimal at-
tendance of 80 % in the exercise programme, a signed
written informed consent and one of the following indi-
cations for CR (acute coronary syndrome (ACS), percu-
taneous coronary intervention (PCI) or coronary artery
bypass grafting (CABG) within 3 months prior to the
start of the CR programme) will be included. All patients
assessed for eligibility will be registered. Exclusion cri-
teria are a contraindication to CR according to the
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Dutch national guideline, mental impairment leading to
inability to cooperate, severe impaired (musculoskeletal)
ability to exercise, signs of cardiac ischemia and/or posi-
tive exercise testing on cardiac ischemia, insufficient
knowledge of the Dutch language, no access, availability
or insufficient knowledge of a computer with internet or
an implanted cardiac device (pacemaker, ICD) [13].
Sample size
Preliminary calculations suggest that for an expected dif-
ference in VO2peak of 3.0 ml/kg/min between the control
and intervention group with an estimated standard devi-
ation of 4.8 ml/min/kg, assuming 90 % power and 5 %
significance level (α = 0.05), a total of 108 patients is
needed to detect a beneficial effect of telemonitoring.
These numbers are based on a previous study that shows
the effects of 52 weeks of CR with combined supervised
and unsupervised exercise sessions [14]. Taking into ac-
count a 10 % dropout we plan to randomise 60 patients
in each group.
Randomisation
At the end of the regular CR programme, patients meet-
ing the in- and exclusion criteria will be informed and
requested to participate. After receiving written in-
formed consent, patients will be randomised in a 1:1
ratio to the intervention group with telemonitoring guid-
ance or the control group with a traditional follow-up
programme by means of a computerised allocation sys-
tem applying an algorithm that prevented the care pro-
viders or the investigators from predicting the outcome
of the randomisation process. This means that the per-
son, who determines if the patient is eligible, at the time
of this decision, is unaware of which group the patient
will be allocated to. The patient and care providers are
not blinded to the intervention.
Telemonitoring/coaching
Patients in the intervention group are equipped with a
smartphone (Samsung Galaxy Ace GT-s5830i, Korea)
and Bluetooth connected heart rate monitor (Zephyr,
Annapolis, USA). Therefore the device is able to register
training mode, training time and also training intensity.
The subjects receive a personal moderate to high intensity
heart rate zone based on their Cardio Pulmonary Exercise
Test (CPET) at T0 and are free to choose which type of ex-
ercise they are going to do. Moderate intensity will be de-
fined as an intensity above their individual first ventilatory
threshold [15]. The patients in the intervention group will
be advised to exercise at least 30 min a day 5 days a week
in the above mentioned training zone. During exercise,
type of exercise, heart rate and duration will be registered.
Fig. 1 Flowchart, illustrating randomisation and testing at different time points
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Afterwards, patients are requested to score their perceived
exertion of training (BORG score). Data will be transferred
to a secured website through a secured wireless connection
(CE registration NL-CAOO2-2014-32838; ISO 27001). Pa-
tients will have access to their individual webpage and their
training history on the smartphone. Here they are able to
see how much and with which intensity they have exer-
cised. They will be contacted by telephone weekly in the
first month, every other week in the second month and
from then on every month until T1. During these tele-
phone calls (10 in total) patients receive further advice on
how to improve their LTPA level. The nurses discuss the
exercise data and use motivational interviewing to motivate
and stimulate the patient.
Traditional follow-up
Traditional follow-up after CR consists of one out-
patient visit 3 months after hospitalisation. During this
visit medication is checked, information about the diag-
nosis is given and possible complaints are discussed. If
necessary addition testing and extra visits are scheduled.
Cardio pulmonary exercise testing
Cardiopulmonary exercise testing will be performed every
visit in both groups using individualised cycle ergometer
ramp protocols on an electro-magnetically braked
cycle ergometer (Lode Corrival, Lode, Groningen, the
Netherlands). Twelve-lead ECG is recorded continuously
and blood pressure is measured every 3 min. Oxygen con-
sumption and CO2 production will be measured breath-
by-breath by ventilatory gas exchange (Metalyzer 3b,
Cortex Biophysics GmbH, Leipzig, Germany).
All patients start with 1 min of rest, thereafter 2 min
of unloaded cycling, an individualised ramp protocol in
order to reach VO2peak between 8 and 12 min, 1 min of
complete rest to measure Heart Rate Recovery (HRR)
and finally a recovery period of 4 min. Patients will be
encouraged to exercise until levelling off of VO2 despite
an increase in workload and/or to a respiratory exchange
ratio >1.10. Afterwards, patients are asked to quantify
their rate of perceived exertion according to the original
BORG score. Peak VO2 will be determined as the mean
value of the final 30 s of exercise. The following criteria
will be used to correlate the CPET at different time
points: <100 ml increase VO2 in the last minute, RER
(Respiratory Exchange Ratio) ≥ 1.10, BORG ≥ 17, HR
(Heart Rate) > 85 % predicted.
Medical history, physical examination and additional
testing
Medical history, medication and co-morbidities will be
screened every visit. During each visit physical examin-
ation length, weight and blood pressure (manual auscul-
tation in seated position) will be measured. Waist and
hip circumference will be measured and skinfold thick-
ness will be determined (biceps, triceps, sub-scapular,
supra-iliac) to calculate lean body mass [16]. Further-
more resting electrocardiogram (supine position) and
lung function test will be executed [17].
Echocardiography
Echocardiographic parameters for cardiac structure and
function will be measured at T0 and T2.
Structure
From the 2-dimensional echocardiogram, diameter of the
aorta, left atrium, left ventricle at end-diastole (LVED) and
at end-systole (LVES), end-diastolic wall thickness of the
intraventricular septum (IVS), and left ventricular poster-
ior wall (LVPW) will be measured in the parasternal long-
axis view, tracing of the area of the left atrium, and
diameter of the vena cava inferior at end expiration will be
measured in the subcostal view, respectively.
Systolic function
Ejection fraction will be calculated using the formula:
(LVEDV–LVESV/LVEDV), where left ventricular end-
diastolic volume (LVEDV) and left ventricular end-systolic
volume (LVESV) from 2-dimensional echocardiograms in
the apical 4-chamber view will be determined using the
biplane Simpson rule method.
Diastolic function
Standard LV inflow pulsed-wave Doppler measurements
at the mitral leaflet tips, including peak flow velocity of
the early rapid filling wave (E[−wave]), peak flow velocity
of the late filling wave due to atrial contraction
(A[−wave]), the E/A ratio,(early deceleration time), and
isovolumetric relaxation time will be measured to assess
global diastolic function. In addition left atrium inflow
pulsed wave velocity Doppler measurements will be
obtained, including pulmonary venous flow velocities in
both diastole (D) and systole (S), and the S/D ratio.
To measure myocardial relaxation, pulsed-wave TDI
measurements at the septal and lateral mitral annulus
will be obtained.
Questionnaires
Subjects will be asked to fill in several validated ques-
tionnaires to assess general health. This includes QOL
(KVL-H), physical functioning (IPAQ-long version),
emotional functioning (PHQ-9, HADS) and social func-
tioning (MPSS) [18]. These questionnaires will be com-
pleted at baseline and after 6 and 12 months.
Blood analysis
Venous blood samples will be obtained after an over-
night fasting period at baseline, after 6 and 12 months.
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Total cholesterol, serum triglycerides, high-density lipo-
protein, low-density lipoprotein, ApoB, HbA1c and glu-
cose are analysed by the biochemical laboratory using
standard procedures for the analyses.
Adverse events
All adverse events will be registered and serious adverse
events (SAE) will also be reported continuously to the
Contract Research Organisation (CRO) Diagram. SAE are
defined as cardiovascular mortality, all-cause mortality,
near sudden cardiac death, ACS, CV intervention/surgery,
CV hospital admission and CV emergency visit.
Care consumption and MACE
The occurrence of events (cardiovascular mortality, all-
cause mortality, near sudden cardiac death, ACS, CV
Intervention/surgery, CV hospital admission, CV emer-
gency visits) and consumption of care (admission days,
outpatient clinic visits, GP visits, interventions, radiology,
nuclear and lab testing) will be collected by a (monthly)
telephone call with the participants throughout the study
period and patients’ electronic medical files.
Data handling
eDream®, an electronic data capture and clinical data
management programme (electronic case report form)
will be used to collect and store the data. The database
will be hosted and secured on the servers of Diagram
and is on-line accessible.
Statistics
All parameters will be analysed on the intention-to-treat
principle. All patients will be analysed in the group they
are randomised to. Categorical variables will be sum-
marised by frequency and percentages. Continuous
variables will be summarised by mean and standard de-
viation as well as median and interquartile range.
The primary treatment comparison is telemonitoring
group versus control group. Student’s t-tests will be used
to examine whether the continuous variables are differ-
ent between the intervention groups at baseline, at
6 months and at 12 months. When necessary the con-
tinuous variables will be transformed to obtain a normal
distribution, or a non-parametric test will be used
(Wilcoxon rank-sum test). Chi Square tests or Fisher’s
exact tests as appropriate will be used to examine
whether the categorical variables are different between
the intervention groups at baseline, at 6 months and at
12 months.
Time until MACE will be described by Kaplan Meier
curves. The Kaplan Meier curves will indicate the occur-
rence of MACE during 1 year of follow-up. Patients who
do not experience an event or are lost to follow-up
without an event are censored. Differences in survival
distributions between the telemonitoring and control
group will be tested using logrank tests.
A two-sided p-value of less than 0.05 will be consid-
ered to be statistically significant in all analyses. Analyses
will be performed with Statistical Analysis System, SAS,
version 9.3 and with the Statistical Package for the Social
Sciences (SPSS, IBM) version 22.0.
Preliminary results
Patient demographics and reasons to refrain from par-
ticipation are shown in Tables 1 and 2. Preliminary re-
sults show that 122 of 299 (40.8 %) consecutive patients
meeting the in- and exclusion criteria were willing to
participate. They are on average 59 years of age and pre-
dominantly male (82,5 %). Main reasons to refrain from
participation are the time investment and doubts con-
cerning the added value.
Discussion
The long term benefits of lifestyle interventions are
often disappointing due to lack of adherence and persist-
ent change in life style. Qualitative research on patients’
perspectives suggests that motivation for lifestyle chan-
ges tends to wane 3 months after the event. Most Dutch
CR programmes though last less than 3 months.
Several studies showed that telehealth interventions
after traditional CR provide an effective risk factor reduc-
tion in secondary prevention. They showed promising re-
sults in encouraging patients to stay active after the acute
rehabilitation phase [19–21]. Moreover Frederix et al. and
Table 1 Patient demographics
Screened Included
Number (%)
Patients screened 299 122
Men 232 (77.7) 101 (82.8)
Women 67 (22.4) 21 (17.2)
Age (mean years) 63.7 59.6
Table 2 Reasons to refrain from participation
Number (%)
Too time consuming 64 (36)
Not convinced of added value 40 (23)
Insufficient computer knowledge 25 (14)
Follow-up in a different location 12 (7)
Physical impairment 12 (7)
Too much traveling time 7 (4)
Problems with coping 6 (3)
Holiday > 1 month or abroad during follow up 5 (3)
Heart rate belt is too much stress 3 (2)
Unknown 3 (2)
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Kraal et al. showed that Telerehabilitation appears to be a
feasible and effective additional and/or alternative form of
rehabilitation, which is more effective and efficient than
centre based CR alone [22, 23]. The TeleCaRe study differ-
entiates itself from other telehealth studies by the length
of the guidance and the follow up after the intervention in
combination with the possibility to monitor type, volume
and intensity of LTPA. Only a few studies looked at a
follow-up period after the telemonitoring period without
an intervention and as a result it is still unclear if tele-
health interventions induce persistent lifestyle change.
Moreover by measuring heart rate during exercise we are,
contrary to studies using a motion sensor, able to monitor
and coach patients to exercise in the right exercise inten-
sity zone and correlate exercise intensity to outcome
parameters [15, 24].
The TeleCaRe study evaluates the effects of extending
a traditional CR programme with telemonitoring guid-
ance for a period of 6 months with a follow-up of
6 months without support. The main aim of the study is
to determine if this extension results in better long-term
effects on physical and mental outcomes, care consump-
tions and QOL than the regular follow-up after cardiac
rehabilitation.
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